0RV2 Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 189.05 |
| 52 Week High | SEK 287.00 |
| 52 Week Low | SEK 137.90 |
| Beta | -0.25 |
| 11 Month Change | 20.34% |
| 3 Month Change | 14.06% |
| 1 Year Change | -20.25% |
| 33 Year Change | 60.17% |
| 5 Year Change | 104.49% |
| Change since IPO | 600.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RV2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.2% | -5.2% | 0.8% |
| 1Y | -20.2% | -20.1% | 6.6% |
Return vs Industry: 0RV2 matched the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0RV2 underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0RV2 volatility | |
|---|---|
| 0RV2 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RV2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RV2's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 104 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| 0RV2 fundamental statistics | |
|---|---|
| Market cap | SEK 16.38b |
| Earnings (TTM) | -SEK 232.86m |
| Revenue (TTM) | SEK 167.14m |
100.2x
P/S Ratio-72.0x
P/E RatioIs 0RV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RV2 income statement (TTM) | |
|---|---|
| Revenue | SEK 167.14m |
| Cost of Revenue | SEK 90.50m |
| Gross Profit | SEK 76.64m |
| Other Expenses | SEK 309.50m |
| Earnings | -SEK 232.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 45.85% |
| Net Profit Margin | -139.32% |
| Debt/Equity Ratio | 0% |
How did 0RV2 perform over the long term?
See historical performance and comparison